Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of PUMCH-E101 in RDH12 Retinopathy
NCT07878572Phase 1Enrolling by invitation
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PUMCH-E101 in RDH12-associated retinopathy, sponsored by Peking Union Medical College Hospital. Primary endpoints: Dose-Limiting Toxicities at 4 weeks, Adverse Events at 52 weeks and 1 more. Started Dec 2025; status: enrolling by invitation.
02
Drugs
PUMCH-E101
03
Conditions
RDH12-associated retinopathy
Beyond the preview
Go deeper on NCT07878572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07878572.